Phase I/Ib Trial of Radiotherapy in Combination with Durvalumab (MEDI4736) Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Latest Information Update: 05 Mar 2025
At a glance
- Drugs Durvalumab (Primary)
- Indications Head and neck cancer; Mouth neoplasm; Squamous cell cancer
- Focus Adverse reactions
- 03 Jun 2024 Planned End Date changed from 19 May 2024 to 19 May 2025.
- 21 Jan 2022 Planned End Date changed from 19 May 2022 to 19 May 2024.
- 21 Jan 2022 Planned primary completion date changed from 25 Jun 2021 to 19 May 2023.